Our CAMP I study is the largest clinical study to date to evaluate the metabolism of children with autism spectrum disorder (ASD). It was funded by a research grant on autism from the National Institutes of Mental Health (NIMH). The details and results of this clinical study were first published in a paper in the scientific journal of Biological Psychiatry and, subsequently, a paper in Autism Research. This research was informed by our three earlier autism studies, which also investigated the connection between metabolism and autism.
Autism Clinical Studies
- Validated our NeuroPointDX autism spectrum disorder (NPDX ASD) blood test which may lead to an earlier ASD diagnosis for some children
- Compared a child’s comprehensive metabolic panel blood plasma sample results to their behavioral evaluation to identify differences in metabolism of children who were diagnosed with ASD
- Conducted at 8 clinical study sites, including some of the leading autism centers in the country
- Enrolled 1,100 children aged 18-48 months old
CAMP I Clinical Sites
This study was funded by a grant from the National Institutes of Mental Health and investments by the Nancy Lurie Marks Family Foundation and the Robert E. and Donna Landreth Family Fund. We are grateful to all of the children and families who participated in the CAMP I clinical study who helped us better understand ASD and develop the NeuroPointDX autism spectrum disorder (NPDX ASD) blood test.